Outcome of Board Meeting
Merck Ltd has informed BSE that the Board of Directors of the Company at its meeting held on December 21, 2015 has approved the following:1. Shifting of the Registered Office of the Company from Shiv Sagar Estate 'A', Dr. Annie Besant Road, Worli, Mumbai -400018 to Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East) w.e.f December 31, 2015.... Merck KGaA, Threshold drug fails in late-stage cancer trials
Germany's Merck KGaA and development partner Threshold Pharmaceuticals said their experimental cancer drug Evofosfamide failed to show the desired effects in two late stage studies.Evofosfa... Merck plans to sell its allergy business unit to cut debt
The sale, which could fetch about $636.42 million, is an attempt by the company to offload its debt after the Sigma Aldrich Corp takeover German drugs and chemicals maker Merck is planning to sell its allergy business, Allergopharma, Bloomberg reported, citing sources. The sale, which could fetch about 600 million euros ($636.42 million), is an [] Financial Results & Limited Review Report for Sept 30, 2015 (Standalone)
Merck Ltd has informed BSE about the Standalone Financial Results & a copy of the Limited Review Report for the period ended September 30, 2015. Merck clears major hurdle to Sigma-Aldrich takeover
"This is another key step towards completing the acquisition of Sigma-Aldrich," Merck executive board member Bernd Reckmann said in a statement on Tuesday. Jubilant Life up on USFDA nod for Rizatriptan Benzoate OD tablets
Rizatriptan Benzoate OD (Orally Disintegrating) Tablets are the generic version of Merck's Maxalt-MLT OD tablets Shareholding Pattern for September 30, 2015
Merck Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015. Closure of Trading Window
Merck Ltd has informed BSE that the Company has issued notification to its employees on September 14, 2015 regarding closure of trading window for them for the purposes of consideration and approval of the un-audited financial results from September 16, 2015 until 24 hours from the publication of the un-audited financial results for the quarter ended September 30, 2015. Outcome of Board Meeting
Merck Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12, 2015, inter alia, has the Board has amended its existing Code on Prevention of Insider Trading to include inter-alia Code of Practices of Fair disclosure of Un-published Price sensitive Information. Financial Results & Limited Review Report for June 30, 2015 (Standalone)
Merck Ltd has informed BSE about the Standalone Financial Results & a copy of the Limited Review Report for the period ended June 30, 2015.